Floatz logo

Avelumab

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

Pfizermonoclonal_antibodyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Talzenna
Pfizer
Phase 1/2CCC

Same molecule, other indications

Avelumab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
urothelial carcinomaDormant
B
Indicative ·
58 / 100
View asset →
bladder transitional cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →